Paper · 31292550
Cited by258
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 347 citations.
1 to 20 of 258
Download this page as JSON| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,598,072 | Interpreting homologous recombination deficiency in rare gynecological cancers: A case of primary mucinous endometrial adenocarcinoma of gastrointestinal type. | Gynecol Oncol Rep | 2026 | https://conductscience.org/library/papers/42598072 | PubMed |
| 42,521,810 | Bridging the gap: integrating hereditary cancer into precision oncology. | Eur J Hum Genet | 2026 | https://conductscience.org/library/papers/42521810 | PubMed |
| 42,498,744 | Chinese expert consensus on precision testing and molecular diagnosis of pancreatic cancer (2025). | Br J Cancer | 2026 | https://conductscience.org/library/papers/42498744 | PubMed |
| 42,308,463 | Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I. | JCO Precis Oncol | 2026 | https://conductscience.org/library/papers/42308463 | PubMed |
| 42,186,016 | Whole genome sequencing in oesophageal adenocarcinoma unmasks potential precision therapies. | BMC Cancer | 2026 | https://conductscience.org/library/papers/42186016 | PubMed |
| 42,132,987 | Why are Some Tissues More Vulnerable? Revisiting Tissue Specificity in Hereditary Cancer Syndromes. | Mol Diagn Ther | 2026 | https://conductscience.org/library/papers/42132987 | PubMed |
| 41,998,785 | Estrogen receptor-positive, BRCA1-deficient breast cancer: BRCA1-epimutated tumors presenting a piece to the puzzle. | Breast Cancer Res | 2026 | https://conductscience.org/library/papers/41998785 | PubMed |
| 41,990,295 | Germline Pathogenic Variants in Homologous Recombination Pathway Genes Are Frequent in Pancreatobiliary Ampullary Carcinoma. | JCO Precis Oncol | 2026 | https://conductscience.org/library/papers/41990295 | PubMed |
| 41,895,280 | Cancer type-specific variation in patterns of driver alterations across 50,000 tumors. | Cancer Cell | 2026 | https://conductscience.org/library/papers/41895280 | PubMed |
| 41,867,230 | Cancer genomic profiling predicts pathogenicity of BRCA1 and BRCA2 variants. | medRxiv | 2026 | https://conductscience.org/library/papers/41867230 | PubMed |
| 41,850,312 | Genomic Profiling in Localized Prostate Cancer: Associations With Biochemical Recurrence and Response to Salvage Radiotherapy. | Cancer Sci | 2026 | https://conductscience.org/library/papers/41850312 | PubMed |
| 41,849,730 | Genomic Features and Response to Poly(ADP-ribose) Polymerase Inhibition in Metastatic Castration-Resistant Prostate Cancer. | JCO Precis Oncol | 2026 | https://conductscience.org/library/papers/41849730 | PubMed |
| 41,785,438 | Impact of Germline BRCA Mutation Status on Antitumor Activity of Modified FOLFIRINOX in Patients With Advanced Pancreatic Cancer: An Exploratory Analysis. | JCO Precis Oncol | 2026 | https://conductscience.org/library/papers/41785438 | PubMed |
| 41,781,623 | Homologous recombination deficiency and hemizygosity drive resistance in breast cancer. | Nature | 2026 | https://conductscience.org/library/papers/41781623 | PubMed |
| 41,724,111 | Quantifying rate-limiting genetic variation in breast and ovarian tumourigenesis. | EBioMedicine | 2026 | https://conductscience.org/library/papers/41724111 | PubMed |
| 41,686,836 | A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2. | Clin Cancer Res | 2026 | https://conductscience.org/library/papers/41686836 | PubMed |
| 41,646,477 | A stratified two-stage tumor molecular profiling algorithm to identify clinically actionable molecular alterations in pancreatic cancer. | ESMO Gastrointest Oncol | 2025 | https://conductscience.org/library/papers/41646477 | PubMed |
| 41,611,726 | Monitoring of circulating tumor DNA in patients with stage II-III breast cancer treated with neoadjuvant chemotherapy. | NPJ Breast Cancer | 2026 | https://conductscience.org/library/papers/41611726 | PubMed |
| 41,424,170 | Subclinical Telomere Biology Disorder in Cancer Patients Heterozygous for the RTEL1 R1264H Founder Variant. | Am J Med Genet A | 2026 | https://conductscience.org/library/papers/41424170 | PubMed |
| 41,210,226 | Targeted therapy in patients with genetic tumor syndromes. | Med Genet | 2025 | https://conductscience.org/library/papers/41210226 | PubMed |
papers-2026-11-12-0.1.0
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/papers/v1/31292550/cited_by